Hawthorn
16 benefits mapped to clinical evidence across supplements.
Dose per serving from products
163 products in our catalogue print how much Hawthorn a serving holds.
Most common: 100 mg to 250 mg, 26% of 163 products.
| Dose per serving | Products |
|---|---|
| 25 mg or less | 7 |
| 25 mg to 50 mg | 11 |
| 50 mg to 100 mg | 23 |
| 100 mg to 250 mg | 43 |
| 250 mg to 500 mg | 31 |
| 500 mg to 1 g | 16 |
| 1 g to 2.5 g | 32 |
Dose per serving from research
9 study groups in 8 studies say how much Hawthorn participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 500 mg to 1 g and 1 g to 2.5 g, 33% of 9 study groups each.
| Daily dose | Study groups |
|---|---|
| 25 mg to 50 mg | 1 |
| 50 mg to 100 mg | 1 |
| 100 mg to 250 mg | 0 |
| 250 mg to 500 mg | 0 |
| 500 mg to 1 g | 3 |
| 1 g to 2.5 g | 3 |
| 2.5 g to 5 g | 0 |
| 5 g to 10 g | 1 |
Benefit Evidence
BP fall reduced, +4.5
SBP/DBP lowered, -7 to -8
Standing BP raised, +5.9
Research sources
Heart health (9)
- [Effects of an herbal crataegus-camphor combination on the symptoms of cardiovascular diseases]
PubMed ID: 10965417
4‑week trial of crataegus+camphor reduced heart-related symptom scores (combination product, cannot isolate hawthorn fully).
- Clinical efficacy of crataegus extract WS 1442 in congestive heart failure NYHA class II
PubMed ID: 11515715
12‑week trial showed trends to improved exercise capacity and lower workload-related cardiovascular index (borderline significance).
- [Clinical study on treatment of carotid atherosclerosis with extraction of polygoni cuspidati rhizoma et radix and crataegi fructus: a randomized controlled trial]
PubMed ID: 24956862
RCT of an extract containing hawthorn reduced carotid IMT and plaque biomarkers—supports cardiovascular/arterial benefit consistent with 'heart support'.
- A randomised double blind placebo controlled clinical trial of a standardised extract of fresh Crataegus berries (Crataegisan) in the treatment of patients with congestive heart failure NYHA II
PubMed ID: 12833999
8‑week RCT: fresh hawthorn extract modestly increased exercise tolerance in mild HF (direct efficacy evidence).
- Efficacy and safety of crataegus extract WS 1442 in comparison with placebo in patients with chronic stable New York Heart Association class-III heart failure
PubMed ID: 12040357
Well-powered RCT in NYHA III showed dose-dependent, significant improvement in exercise capacity and symptoms (strong evidence).
- [Actions of standardized extracts of Crataegus berries on exercise tolerance and quality of life in patients with congestive heart failure]
PubMed ID: 11715631
3‑month RCT: modest increase in exercise time and QoL in mild-to-moderate HF (positive clinical trial).
- Gelanxinning capsule improves coronary microvascular dysfunction by inhibiting inflammation and restoring endothelial function
PubMed ID: 37782173
Randomized trial in CAD patients (multi‑herb product including hawthorn) improved endothelial/microvascular biomarkers supporting cardiovascular benefit, though effect not attributable to hawthorn alone.
- [Crataegus Special Extract WS 1442 in NYHA II heart failure. A placebo controlled randomized double-blind study]
PubMed ID: 8375791
Randomized trial in NYHA II: WS1442 improved pressure–rate product and symptoms (direct cardiac benefit).
- [Crataegus Special Extract WS 1442. Assessment of objective effectiveness in patients with heart failure (NYHA II)]
PubMed ID: 8974970
Multicenter RCT: WS 1442 improved objective exercise cardiac performance and symptoms in mild HF (strong direct evidence).
Blood circulation (8)
- The effect of Camphor-Crataegus berry extract combination on blood pressure and mental functions in chronic hypotension--a randomized placebo controlled double blind design
PubMed ID: 18929475
Camphor+Crataegus combo quickly raised BP in hypotensive women and improved related cognitive performance — supports short-term circulatory improvement (confounded by camphor).
- [Clinical study on treatment of carotid atherosclerosis with extraction of polygoni cuspidati rhizoma et radix and crataegi fructus: a randomized controlled trial]
PubMed ID: 24956862
Reduction in carotid IMT and plaque implies improved arterial health/circulatory status after treatment including hawthorn extract.
- Efficacy and safety of crataegus extract WS 1442 in comparison with placebo in patients with chronic stable New York Heart Association class-III heart failure
PubMed ID: 12040357
Dose-dependent increases in maximal tolerated workload reflect improved cardiovascular performance/circulation.
- Camphor-Crataegus berry extract combination dose-dependently reduces tilt induced fall in blood pressure in orthostatic hypotension
PubMed ID: 12487321
Camphor–hawthorn formulation reduced orthostatic BP fall and raised mean arterial pressure (direct circulatory stabilization evidence, but camphor present).
- Antihypertensive effect of Iranian Crataegus curvisepala Lind.: a randomized, double-blind study
PubMed ID: 15700749
4+ month trial in mild hypertension showed systolic/diastolic BP reductions — relevant to overall circulatory status though effect is lowering rather than increasing BP.
- A randomized trial of Korodin Herz-Kreislauf-Tropfen as add-on treatment in older patients with orthostatic hypotension
PubMed ID: 16008114
Korodin (contains Crataegus) modestly improved standing MAP in older patients with orthostatic hypotension — direct evidence for improved short-term circulation.
- D-camphor-crataegus berry extract combination increases blood pressure and cognitive functioning in the elderly - a randomized, placebo controlled double blind study
PubMed ID: 19560327
Hawthorn-containing product transiently increased BP and continuous hemodynamics, indicating short-term circulation effects (combination product).
- [Crataegus Special Extract WS 1442. Assessment of objective effectiveness in patients with heart failure (NYHA II)]
PubMed ID: 8974970
Improved exercise cardiac performance and symptoms implies better central/peripheral circulation in HF patients.
Endurance (6)
- [Crataegus Special Extract WS 1442 in NYHA II heart failure. A placebo controlled randomized double-blind study]
PubMed ID: 8375791
Improved pressure–rate product at fixed workload indicates better cardiovascular stamina during exertion.
- A randomised double blind placebo controlled clinical trial of a standardised extract of fresh Crataegus berries (Crataegisan) in the treatment of patients with congestive heart failure NYHA II
PubMed ID: 12833999
8‑week RCT demonstrated a modest but significant increase in exercise tolerance (watts).
- [Crataegus Special Extract WS 1442. Assessment of objective effectiveness in patients with heart failure (NYHA II)]
PubMed ID: 8974970
Multicenter RCT showed improved exercise cardiac performance and workload in mild HF (strong stamina signal).
- Clinical efficacy of crataegus extract WS 1442 in congestive heart failure NYHA class II
PubMed ID: 11515715
Trends toward improved exercise tolerance over 12 weeks suggest possible stamina gains (borderline significance).
- [Actions of standardized extracts of Crataegus berries on exercise tolerance and quality of life in patients with congestive heart failure]
PubMed ID: 11715631
Three-month treatment increased exercise time and Dyspnea–Fatigue Index, indicating better stamina.
- Efficacy and safety of crataegus extract WS 1442 in comparison with placebo in patients with chronic stable New York Heart Association class-III heart failure
PubMed ID: 12040357
Clear dose-dependent, statistically significant increase in maximal tolerated workload supports increased stamina.
Energy & Fatigue (5)
- [Crataegus Special Extract WS 1442 in NYHA II heart failure. A placebo controlled randomized double-blind study]
PubMed ID: 8375791
Improved exercise workload and symptoms likely correlate with increased perceived energy.
- [Crataegus Special Extract WS 1442. Assessment of objective effectiveness in patients with heart failure (NYHA II)]
PubMed ID: 8974970
Objective and subjective cardiac improvements are consistent with greater daily energy and functional capacity.
- [Actions of standardized extracts of Crataegus berries on exercise tolerance and quality of life in patients with congestive heart failure]
PubMed ID: 11715631
Increased exercise time and QoL scores suggest patients feel more energetic.
- Efficacy and safety of crataegus extract WS 1442 in comparison with placebo in patients with chronic stable New York Heart Association class-III heart failure
PubMed ID: 12040357
Substantial, dose-dependent improvements in maximal tolerated workload imply increased functional energy in HF patients.
- A randomised double blind placebo controlled clinical trial of a standardised extract of fresh Crataegus berries (Crataegisan) in the treatment of patients with congestive heart failure NYHA II
PubMed ID: 12833999
Modest increase in exercise tolerance could translate into somewhat more energy.
Blood pressure (5)
- Camphor-Crataegus berry extract combination dose-dependently reduces tilt induced fall in blood pressure in orthostatic hypotension
PubMed ID: 12487321
Camphor–hawthorn drops raised mean arterial pressure and reduced orthostatic fall (useful for orthostatic hypotension; camphor confounds attribution).
- Antihypertensive effect of Iranian Crataegus curvisepala Lind.: a randomized, double-blind study
PubMed ID: 15700749
Randomized 4+ month trial in mild hypertension showed statistically significant SBP and DBP reductions vs placebo — strong direct evidence for BP-lowering.
- A randomized trial of Korodin Herz-Kreislauf-Tropfen as add-on treatment in older patients with orthostatic hypotension
PubMed ID: 16008114
Korodin (contains hawthorn) improved standing MAP in orthostatic hypotension — supports BP-modulating effects in specific populations.
- Hypotensive effects of hawthorn for patients with diabetes taking prescription drugs: a randomised controlled trial
PubMed ID: 16762125
Randomized trial in type 2 diabetics found a small but significant reduction in diastolic BP (−2.6 mmHg) with hawthorn — moderate support.
- The effect of Camphor-Crataegus berry extract combination on blood pressure and mental functions in chronic hypotension--a randomized placebo controlled double blind design
PubMed ID: 18929475
Camphor+Crataegus product raised BP in hypotensive women acutely — indicates capacity to alter BP, though confounded and direction depends on baseline BP.
Inflammation (4)
- Crataegus laevigata decreases neutrophil elastase and has hypolipidemic effect: a randomized, double-blind, placebo-controlled trial
PubMed ID: 21242072
Randomized trial in diabetic patients showed a clear decrease in neutrophil elastase (NE), an inflammatory marker (between-group significance), supporting anti-inflammatory activity.
- [Clinical study on treatment of carotid atherosclerosis with extraction of polygoni cuspidati rhizoma et radix and crataegi fructus: a randomized controlled trial]
PubMed ID: 24956862
Trial of polygonum + hawthorn extracts reduced serum hs-CRP and MMP-1 and improved plaque measures—strongest direct evidence for anti-inflammatory effects among provided studies.
- Gelanxinning capsule improves coronary microvascular dysfunction by inhibiting inflammation and restoring endothelial function
PubMed ID: 37782173
Gelanxinning capsule (contains hawthorn) RCT showed reductions in inflammatory markers (NLRP3, IL‑1) — supports anti‑inflammatory effect of the multi‑herb product.
- Treating unstable angina with detoxifying and blood-activating formulae: A randomized controlled trial
PubMed ID: 34416295
Herbal granule (includes hawthorn) produced reductions in hs‑CRP, TNF‑α, IL‑6 and improved pro/anti‑inflammatory ratios versus control.
Respiratory comfort (3)
- Efficacy and safety of crataegus extract WS 1442 in comparison with placebo in patients with chronic stable New York Heart Association class-III heart failure
PubMed ID: 12040357
Reduction in heart‑failure symptoms with improved exercise tolerance likely includes reduced dyspnea.
- [Crataegus Special Extract WS 1442. Assessment of objective effectiveness in patients with heart failure (NYHA II)]
PubMed ID: 8974970
Symptom improvements in HF included breathlessness measures (patient-reported), supporting easier breathing.
- [Actions of standardized extracts of Crataegus berries on exercise tolerance and quality of life in patients with congestive heart failure]
PubMed ID: 11715631
Dyspnea–Fatigue Index improved in a 3‑month trial, indicating easier breathing with WS1442 in mild–moderate HF.
Vitality (3)
- [Crataegus Special Extract WS 1442. Assessment of objective effectiveness in patients with heart failure (NYHA II)]
PubMed ID: 8974970
Objective and subjective cardiac benefits (exercise performance and QoL) support improved general vitality.
- [Actions of standardized extracts of Crataegus berries on exercise tolerance and quality of life in patients with congestive heart failure]
PubMed ID: 11715631
Increased exercise time and QoL measures indicate better perceived vitality.
- Efficacy and safety of crataegus extract WS 1442 in comparison with placebo in patients with chronic stable New York Heart Association class-III heart failure
PubMed ID: 12040357
Significant improvements in exercise capacity and symptoms likely enhance overall vitality in HF patients.
Stress & Anxiety (2)
- Double-blind, randomised, placebo-controlled study to evaluate the efficacy and safety of a fixed combination containing two plant extracts (Crataegus oxyacantha and Eschscholtzia californica) and magnesium in mild-to-moderate anxiety disorders
PubMed ID: 14741074
Large randomized trial: combination (Crataegus + others) significantly reduced Hamilton anxiety scores (hawthorn part of multi-ingredient product).
- Effects of a Scutellaria baicalensis/Crataegus laevigata, magnesium and chromium supplement on stressed individuals: A randomised, double-blind, placebo-controlled, crossover trial
PubMed ID: 41194549
Trait anxiety decreased significantly in a small crossover study of a supplement including hawthorn, but formulation contained multiple active ingredients.
Cholesterol (2)
- Efficacy of Crataegus Extract Mixture on Body Fat and Lipid Profiles in Overweight Adults: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial
PubMed ID: 38398818
Hawthorn‑containing extract produced a clinically meaningful triglyceride reduction (−28.4 mg/dL; −20.2%) in an RCT—evidence for improved lipid profile though LDL/total cholesterol changes not specified.
- Crataegus laevigata decreases neutrophil elastase and has hypolipidemic effect: a randomized, double-blind, placebo-controlled trial
PubMed ID: 21242072
Within-group LDL (-12.3 mg/dL) and non-HDL decreases were observed in the treatment arm of a randomized trial; between-group lipid differences were not significant at 6 months, so evidence is moderate but limited.
Vascular health (2)
- [Clinical study on treatment of carotid atherosclerosis with extraction of polygoni cuspidati rhizoma et radix and crataegi fructus: a randomized controlled trial]
PubMed ID: 24956862
Direct reduction in carotid intima-media thickness and plaque measures in a hawthorn-containing herbal extract trial—strong evidence for arterial benefit in these data.
- Gelanxinning capsule improves coronary microvascular dysfunction by inhibiting inflammation and restoring endothelial function
PubMed ID: 37782173
Improvements in endothelial/microvascular biomarkers in CAD patients (multi‑herb product including hawthorn) are consistent with arterial health benefits, though hawthorn's individual role is not isolated.
Digestive support (1)
- [Umbilical therapy combined with moxibustion for autumn diarrhea in children]
PubMed ID: 31397127
Traditional herbal patch containing hawthorn plus moxibustion improved diarrhea outcomes—supports an effect on digestive recovery though multi‑component.
Illness recovery (1)
- [Umbilical therapy combined with moxibustion for autumn diarrhea in children]
PubMed ID: 31397127
Herbal patch (contains hawthorn) + moxibustion shortened diarrhea recovery vs control in an RCT; multi‑ingredient/adjunct therapy limits attribution.
Cell health (1)
- [Clinical study on treatment of carotid atherosclerosis with extraction of polygoni cuspidati rhizoma et radix and crataegi fructus: a randomized controlled trial]
PubMed ID: 24956862
Plaque biomarker changes (MMP-1/TIMP-1) and IMT reduction suggest vascular tissue-protective effects from the herbal combination that included hawthorn.
Swelling relief (1)
- [Clinical study on treatment of carotid atherosclerosis with extraction of polygoni cuspidati rhizoma et radix and crataegi fructus: a randomized controlled trial]
PubMed ID: 24956862
Reduction in hs-CRP (an inflammation marker) after treatment including hawthorn suggests potential for less systemic inflammation/swelling.
Sleep quality (1)
- Effects of a Scutellaria baicalensis/Crataegus laevigata, magnesium and chromium supplement on stressed individuals: A randomised, double-blind, placebo-controlled, crossover trial
PubMed ID: 41194549
A multi‑ingredient supplement that included Crataegus (hawthorn) increased total sleep time by ~27 min in a small crossover RCT; cannot attribute effect solely to hawthorn.
Similar by evidence
Supplements the same benefits carry qualifying findings for — a fact about the evidence graph, not a recommendation to swap.
Products with Hawthorn
Search all512 products whose verified label declares Hawthorn — not every bottle that mentions it in a title.